Drug
Mesalamine
Mesalamine: highest development phase Post-Market, developed by Bausch Health, Takeda. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Bausch Health, Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| Mesalamine (5-aminosalicylic acid, Apriso) NCT01090102 | Post-Market | HIV Infections |
| LIALDA | Approved |
Latest
No recent events.
Follow Mesalamine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.